Compare LASE & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LASE | TELA |
|---|---|---|
| Founded | 2019 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.0M | 36.7M |
| IPO Year | 2021 | 2019 |
| Metric | LASE | TELA |
|---|---|---|
| Price | $0.96 | $0.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.31 |
| AVG Volume (30 Days) | ★ 3.1M | 348.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.54 | 34.80 |
| EPS | ★ N/A | N/A |
| Revenue | $721,185.00 | ★ $69,300,000.00 |
| Revenue This Year | N/A | $18.41 |
| Revenue Next Year | N/A | $15.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 18.56 |
| 52 Week Low | $0.38 | $0.67 |
| 52 Week High | $6.77 | $2.52 |
| Indicator | LASE | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 38.92 | 52.50 |
| Support Level | $0.38 | $0.67 |
| Resistance Level | $2.54 | $1.22 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 50.72 | 84.15 |
Laser Photonics Corp is an integrated manufacturing company for photonics-based industrial products and solutions, laser cleaning technologies. Its laser-blasting technologies are focused on disrupting the sandblasting and abrasives blasting markets. The company offers a portfolio of integrated laser-blasting solutions for corrosion control, rust removal, de-coating, pre-welding and post-welding, laser cleaning, and surface conditioning. Its laser-blasting solutions are applicable in every industry dealing with materials processing, including automotive, aerospace, healthcare, consumer products, shipbuilding, aerospace, machine manufacturing, nuclear maintenance and de-commissioning, and surface coating.
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.